@article{891705e2ecfb4aeb9a7ccf5b6b5f6355,
title = "Combination molecular therapies for spinal muscular atrophy: How much is enough?",
author = "Mathews, {Katherine D.} and Iannaccone, {Susan T.}",
note = "Funding Information: Dr. Katherine D. Mathews receives funding from the NIH (U54 NS053672) and the Centers for Disease Control. She serves as an advisory board member for MDA and the FSH Society; is a board member for the Friedreich Ataxia Research Alliance (FARA); receives clinical trial funding from PTC Therapeutics, Sarepta Therapeutics, Pfizer, Santhera, Reata, Italfarmaco, CSL Behring; and serves as an industry consultant for Sarepta, Santhera, Avexis, and PTC (no personal compensation). Dr. Susan Iannaccone receives funding from NIH and MDA. She has industry research funding from PTC Therapeutics, Sarepta, FibroGen, Regeneron, Mallinkrodt, Capricor and serves on Advisory Boards for AveXis, Biogen, Sarepta.",
year = "2021",
month = mar,
doi = "10.1002/mus.27109",
language = "English (US)",
volume = "63",
pages = "279--281",
journal = "Muscle and Nerve",
issn = "0148-639X",
publisher = "John Wiley and Sons Inc.",
number = "3",
}